A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...
A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...
An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...
8h
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...
A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...
The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...
Dropping everything-or being forced to-for COVID-19 had widespread effects. On this fifth anniversary of the pandemic, three ...
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback